

Covalon To Showcase AquaGuard® And Iv Clear™ Products To Over 9,000 Nurses At Prestigious ANCC Magnet Conference

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Oct. 24, 2018-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV) (OTCQX:CVALF), an advanced medical technologies company, today announces that it will be showcasing newly-acquired moisture barrier line AquaGuard® as part of its portfolio of infection prevention products at the 2018 American Nurses Credentialing Center National Magnet Conference (the "Magnet Conference"). The Magnet Conference will take place at the Colorado Convention Centre in Denver, Colorado, from October 24th to 26th 2018, and will be Covalon's first exhibition of AquaGuard and IV Clear™ together as part of Covalon's product portfolio.

The Magnet Conference is a great opportunity for Covalon's new and highly talented United States sales team to strengthen its already strong relationships with clinicians and hospital staff that make clinical use and purchasing decisions on Covalon's product portfolio – shower protection, vascular access dressings, surgical site management products, and advanced wound care dressings.

"The Magnet Conference is a showcase for the best nursing practices, and we are excited to present both IV Clear and AquaGuard to over 9,000 nursing professionals during the show," said Brian Pedlar, Chief Executive Officer of Covalon. "Now that Covalon has a United States sales force and customer base of over 1,500 hospitals and clinics, the opportunity to introduce IV Clear and Covalon's other world-class infection prevention products mean that many of the nurses at the Magnet Conference will have a hands-on opportunity to see why clinicians and patients love both IV Clear and AquaGuard. The ability for Covalon to directly sell its strong portfolio of infection management products such as IV Clear, MediClear Pre-Op, SurgiClear, and AquaGuard into an established hospital base in the United States is truly transformative to Covalon."

On October 1st 2018, Covalon announced that it had closed the acquisition of AquaGuard, the Seattle, Washington-based division of medical technologies company Cenorin, LLC. AquaGuard's specialized products provide patients with crucial moisture protection for wound, surgical, and vascular access sites throughout the body while showering, which is an important step to protect patients from infections.

The Magnet Conference runs from October 24-26 2018, and Covalon will be exhibiting in booth #764 during all exhibit hours throughout the conference. The Magnet Recognition Program® ("Magnet") was developed by the American Nurses Credentialing Center (ANCC) to recognize healthcare organizations that provide exceptional nursing care and to uphold the tenets of professional nursing practice. Magnet is the leading source of successful nursing practices and strategies worldwide and expects over 9,000 nursing professionals from leading hospitals in the United States and 20 other countries to attend this year's conference.

About Covalon

Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products, and services address the advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon's technologies are used to prevent, detect, and manage medical conditions in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device coatings. To learn more about Covalon, visit our website at www.covalon.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including completion of integration of the AquaGuard acquisition, the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181024005190/en/>

Source: Covalon Technologies Ltd.

Covalon Technologies Ltd.

Brian Pedlar, 905-568-8400 x 233

CEO

bpedlar@covalon.com

Toll free: 1-877-711-6055

Web site: www.covalon.com

Twitter: @covalon

<https://ir.covalon.com/press-releases?item=120>